Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  LMB-2 immunotoxin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-6 of 6 for your search:
Start Over
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 040121, 04-C-0121, NCI-04-C-0121, NCI-6074, 6074, NCT00080821, NCT00077922
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 040142, 04-C-0142, NCI-04-C-0142, NCI-5943, NCT00085085, NCT00080535
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000064729, NCI-96-C-0064F, NCI-T95-0042N, T95-0042, NCT00002765
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 6 months to 21 years
Sponsor: NCI
Protocol IDs: CDR0000367333, NCI-04-C-0168, NCI-5903, 5903, NCT00085150
Pilot Study of Fludarabine Phosphate and Cyclophosphamide Followed By LMB-2 Immunotoxin in Patients With CD25-Positive Hodgkin's Lymphoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0240, NCI-P6761, 7835, NCI-7835, NCT00389506
Start Over